Get access

Reply to: Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

Authors

  • Madison T. Gray MSc,

    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Search for more papers by this author
  • Douglas A. Gray PhD,

    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Search for more papers by this author
  • John M. Woulfe MD, PhD, FRCP(C)

    Corresponding author
    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    3. Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    4. Department of Pathology & Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
    • Correspondence to: John M. Woulfe, Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Box 926, 501 Smyth Road, Ottawa, Ontario, Canada, E-mail: jwoulfe@ottawahospital.on.ca

    Search for more papers by this author

  • Funding agencies: This study was supported by The Parkinson's Society of Canada and the Michael J. Fox Foundation

  • Relevant conflicts of interest/financial disclosures: DAG and JMW jointly hold a Rapid Response Innovation Award from the Michael J. Fox Foundation. JMW has received an honorarium from Teva Pharmaceutical for a presentation on PD.

  • Full financial disclosures and author roles may be found in the online version of this article.

No abstract is available for this article.

Get access to the full text of this article

Ancillary